Wingstop Inc
Change company Symbol lookup
Select an option...
WING Wingstop Inc
PUMP ProPetro Holding Corp
CHK Chesapeake Energy Corp
SALM Salem Media Group Inc
UGAZ VelocityShares 3x Long Natural Gas ETN Linked to the S&P GSCI? Natural Gas Index ER
UBSI United Bankshares Inc
LTM LATAM Airlines Group SA
TRGP Targa Resources Corp
PFE Pfizer Inc
SOIEF Stolt-Nielsen Ltd
Go

Consumer Discretionary : Hotels, Restaurants & Leisure | Small Cap Growth
Company profile

Wingstop Inc. is franchisor and operator of restaurants that specializes in cooked-to-order, hand-sauced and tossed chicken wings. The Company operates through two segments: Franchise and Company. As of December 31, 2016, the Company offers its guests 11 flavors on bone-in and boneless chicken wings paired with hand-cut, seasoned fries and sides. It is a casual chicken wings-focused restaurant chain with various concepts, which include wings as add-on menu items or focus on wings in a bar or sports-centric setting. The flavors include Atomic, Mango Habanero, Cajun, Original Hot, Louisiana Rub, Mild, Hickory Smoked BBQ, Lemon Pepper, Garlic Parmesan, Hawaiian and Teriyaki. It offers various order options, including eat-in, to go, individual, combo meals and family packs. The Company maintains Website hosting, and manages the development and maintenance of the mobile Wingstop application. It markets Wingstop products, services and restaurants through the Website, www.wingstop.com.

Closing Price
$122.16
Day's Change
0.21 (0.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
124.22
Day's Low
120.33
Volume
(Below Average)
Volume:
552,714

10-day average volume:
665,867
552,714

J&J has a COVID-19 vaccine candidate, Phase 1 trials to start in September

7:38 am ET March 30, 2020 (MarketWatch)
Print

Shares of Johnson & Johnson (JNJ) gained 5% in premarket trading on Monday after the company said it had identified a lead candidate in its efforts to develop a COVID-19 vaccine. J&J said Monday it plans to begin Phase 1 clinical trials of the vaccine candidate in humans in September, and the investigational vaccine may be ready for emergency use authorization from the Food and Drug Administration by early 2021. The company is also scaling up its vaccine manufacturing capabilities in the U.S. and abroad as part of its commitment to bring "an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use." A number of companies including Moderna Inc. (MRNA) are developing vaccines that would prevent infections from the novel coronavirus that has sickened more than half a million people worldwide. Year-to-date, J&J's stock is down 15%, while the S&P 500 has tumbled 21%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

March 30, 2020 07:38 ET (11:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.